Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity

Area of Science:

• Biomedical Engineering
• Cancer Therapy
• Drug Delivery Systems

Background:

• Mesenchymal Stromal Cells (MSCs) are explored for targeted drug delivery.
• Previous work showed bone-marrow-derived MSCs (BM-MSCs) can incorporate and release Paclitaxel (PTX).

Purpose of the Study:

• To evaluate the stability and metabolite profile of Paclitaxel (PTX) after incorporation into MSCs.
• To confirm the therapeutic potential of drug-loaded MSCs for cancer treatment.

Main Methods:

• MSCs were loaded with Paclitaxel (PTX).
• The stability of PTX and its metabolites released by MSCs were analyzed under standard cell culture conditions.

Main Results:

• MSCs did not release less active metabolites (3-OH-PTX, 6-OH-PTX).
• MSCs released active PTX and the biologically active isomer 7-Epitaxol.
• Priming MSCs with PTX did not alter the drug's inherent activity.

Conclusions:

• Drug-primed MSCs offer a viable biological-device for targeted PTX delivery to tumor sites.
• This approach enhances drug efficacy and target selectivity in cancer therapy.
• MSC-mediated drug delivery avoids genetic manipulation, simplifying the therapeutic strategy.